[PDF] Top 20 Sistema informático de gestión de talento humano del gobierno autónomo provincial del Carchi.

... of BM is 39% versus 20%. The authors hypothesize that early aggressive locoregional and systemic treatment could better control regional disease, which in turn affects the development of brain relapses. In accordance ... See full document

... Disease stage is a vital clinical factor that is used to predict prognosis in SCLC. Although the seventh edition of the TNM classification for lung cancer has been proposed, the two-stage system is still ... See full document

... vs. non- epidermoid), gender (female ...large cell and adenosquamous histologies, and performance score due to the design of the treatment protocol, which was limited to patients classified by RPA ... See full document

... Brain MRI at 7 months after HA-PCI completion showed a 36 × 31 mm, well-marginated, heterogeneously enhancing mass in the right HA (perihippocampal) region with sur- rounding edema (Figure 2). The patient’s symptoms ... See full document

... Modern radiation techniques such as intensity-modulated radiotherapy permit administration of high radiation doses with avoidance of the perihippocampal regions. Neverthe- less, the potential benefit of hippocampal ... See full document

... these patients are provided in Table ...squamous cell carcinoma, 17 cases of adenocarcinoma, three cases of large cell car- cinoma, three cases of adenosquamous carcinoma, and two cases of ... See full document

... MATERIALS AND METHODS: A prospective study by use of DTI and conventional T2-weighted MR images was performed with a 1.5T unit with 16 patients with small cell lung cancer and ... See full document

... with cranial MRI. PCI was delivered exclusively in patients who demonstrated good response to primary treatment and no signs of BM on repeat ... See full document

... those patients who achieved complete remission after induction therapy [3, ...in patients with LS-SCLC, significant improve- ments in PFS and OS for “early” arm and “late” arm was observed, and the ... See full document

... All variables in this study were statistically analyzed using the statistical analysis software SPSS version 19.0 (IBM Corp., Armonk, NY USA). The Hardy – Weinberg equili- brium test was performed for the 4397T>C ... See full document

... many patients opted out of cancer-specific treatment for various ...of patients with stages I to III non-small cell lung cancer (NSCLC) who opted out of ... See full document

... likely to benefit from EGFR-TKI [41–43]. Recently a phase III randomized study has shown that patients with a “poor proteomic score” had inferior OS with EGFR-TKI compared to chemotherapy [44]. Other studies ... See full document

... in lung cancer is the in-availability of vali- dated serum tumor markers which could assist in diagnosis and may spare the patient unnecessary interventional diagnostic ...in lung cancer ... See full document

... in non-small cell lung cancer (NSCLC), overall survival is still ...anti-idiotypic cancer vaccine that targets NeuGcGM3 tumor asso- ciated ...NSCLC patients with ... See full document

... [1]. Lung cancer is one of the prime causes of cancer mortal- ity worldwide because of its metastatic properties [2] and potential for ...that cancer stem cells (CSCs), found in solid tumors, ... See full document

... This study revealed for the first time that elevated tumor PDPN expression on both the mRNA level and the protein level has a significant impact on clinicopathological features (pleural invasion, LVI, and lymph node ... See full document

... most patients have metastatic disease at the time of diagnosis. Small cell lung cancer initially responds well to chemotherapy and radiation and surgery should be considered only for ... See full document

... including cell spreading, cell adhesion and cell migra- tion ...from patients with interstitial pneumonia ...in patients with asthma and cirrhotic liver [14, ...exacerbated lung ... See full document

... licence of Amgen]-Basel-Switzerland) was the first therapeu- tic recombinant G-CSF product approved by the US Food and Drug Administration (FDA). Filgrastim differs in structure from human G-CSF by lacking ... See full document

... those patients whose plasma circulating free DNA (cfDNA) was analyzed to detect T790M mutations, detailed information about the methods and results of cfDNA analysis was also collected from medical ... See full document